Antuña Samuel, Barco Raúl, Martínez Diez José M, Sánchez Márquez José Miguel
Department of Orthopaedic Surgery, Hospital Universitario La Paz, Madrid, Spain.
Acta Orthop Belg. 2013 Feb;79(1):25-30.
The objective of this study was to prospectively evaluate the feasibility of a large- scale project on the influence of local application of Platelet Rich Fibrin (PRF) on the functional outcome and integrity of the arthroscopically repaired tendons in patients with massive tears of the rotator cuff. A prospective, randomized pilot clinical trial was performed on 28 patients (22 females, 6 males) with an average age of 65 years (range: 53 to 77) undergoing complete arthroscopic repair of a massive rotator cuff tear. After the repair was completed, 6 ml PRF (Vivostat) was locally applied to the repair site in 14 patients; no similar action was done in the other 14 patients. All patients underwent a clinical examination and an arthro-MRI to evaluate the integrity of the repair, one year after the operation. They were followed clinically for a minimum of 2 years. Functional outcome was evaluated with the Constant and DASH scores. There were no reported complications in either group. None of the patients was lost to follow-up. Globally, the Constant score improved from 45 preoperatively (range: 25 to 65) to 64 at one year (range: 20 to 79) (p < 0.001), with no significant change at two years (mean 63, range: 20 to 77). The VAS for pain improved from 5.6/10 preoperatively to 1.7/10 at the most recent examination (p < 0.001). All but two patients were satisfied. With the numbers of patients available, we could not detect a significant difference in the preoperative (46 vs. 43; p = 037) or postoperative Constant score (61 vs. 68; p = 0.125) between the control group and the PRF group. On arthro-MRI, 19 of the 28 patients (68%) were found to have a large re-tear : 10/14 in the PRF group and 9/14 in the control group. Local application of autologous PRF to the repair site of massive rotator cuffs fully reconstructed arthroscopically failed to improve the clinical outcome and the healing rate, compared with a standard repair. However, a large-scale study would be necessary to confirm these results.
本研究的目的是前瞻性评估一项大型项目的可行性,该项目旨在研究局部应用富血小板纤维蛋白(PRF)对肩袖巨大撕裂患者关节镜修复肌腱功能结局和完整性的影响。对28例患者(22例女性,6例男性)进行了一项前瞻性、随机试验性临床试验,这些患者平均年龄为65岁(范围:53至77岁),均接受了肩袖巨大撕裂的完全关节镜修复。修复完成后,14例患者在修复部位局部应用6ml PRF(Vivostat);另外14例患者未进行类似操作。所有患者在术后一年均接受了临床检查和关节MRI检查,以评估修复的完整性。对他们进行了至少2年的临床随访。功能结局采用Constant和DASH评分进行评估。两组均未报告并发症。没有患者失访。总体而言,Constant评分从术前的45分(范围:25至65分)提高到术后一年的64分(范围:20至79分)(p<0.001),术后两年无显著变化(平均63分,范围:20至77分)。疼痛视觉模拟评分(VAS)从术前的5.6/10改善至最近一次检查时的1.7/10(p<0.001)。除两名患者外,所有患者均表示满意。鉴于可用患者数量,我们未检测到对照组和PRF组在术前(46对43;p=0.37)或术后Constant评分(61对68;p=0.125)上存在显著差异。在关节MRI检查中,28例患者中有19例(68%)出现大的再撕裂:PRF组10/十四例,对照组9/14例。与标准修复相比,在关节镜下完全重建的肩袖巨大撕裂修复部位局部应用自体PRF未能改善临床结局和愈合率。然而,需要进行大规模研究来证实这些结果。